Literature DB >> 1986629

The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists?

C W Tyler1, N C Lee, S J Robboy, R J Kurman, A L Paris, P A Wingo, G D Williamson.   

Abstract

The Cancer and Steroid Hormone Study, a multicenter, population-based, case-control study of ovarian, breast, and endometrial cancer in women 20 to 54 years of age, permitted the diagnoses of contributing pathologists to be compared with those of a panel of three gynecologic pathologists. A diagnosis of ovarian cancer was made by contributing pathologists on 477 subjects. Agreement between the two groups of pathologists was 97% for primary epithelial ovarian cancer and 89% for primary nonepithelial ovarian malignancies. Agreement on diagnosis of major cellular subtypes of ovarian malignancy ranged between 73% for endometrioid cancer and 100% for clear cell carcinomas. We conclude that the diagnosis of pathologic features of primary ovarian cancer is highly predictable. Nonetheless, diagnosis by histologic type varies sufficiently that a review process should be considered for clinical or investigative decisions involving specific histologic diagnoses of ovarian cancer.

Entities:  

Mesh:

Year:  1991        PMID: 1986629     DOI: 10.1016/0002-9378(91)90628-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  The influence of conservative surgical practices for malignant ovarian germ cell tumors.

Authors:  John K Chan; Krishnansu S Tewari; Sarah Waller; Michael K Cheung; Jacob Y Shin; Kathryn Osann; Daniel S Kapp
Journal:  J Surg Oncol       Date:  2008-08-01       Impact factor: 3.454

2.  [Specialized histopathological second opinion of advanced ovarian cancer. Experiences with collectives from prospective randomized phase III studies].

Authors:  S Kommoss; J Pfisterer; A du Bois; D Schmidt; F Kommoss
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

3.  [Central pathology review. Inclusion criterion for clinical studies of ovarian carcinomas?].

Authors:  F Kommoss; S Kommoss; D Schmidt; A du Bois; J Pfisterer
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

4.  Endometriosis: A Malignant Fingerprint.

Authors:  Christopher DeAngelo; Megan Burnett Tarasiewicz; Athena Strother; Heather Taggart; Caron Gray; Meaghan Shanahan; Christopher Glowacki; Jimmy Khandalavala; Erin Talaska; Andrea Kinnan; John Joseph Coté; Adrienne Perfilio Edwards; Gina Harper-Harrison; Murray Joseph Casey; Traci-Lynn Hirai; Sarah Schultz; Lynnea Stines; Roma Vora; Dominique Boudreau; Jennifer Burgart; Meredith Shama; Trevor Watson; Lisa Strasheim; Rachel Thompson; Rachel Lawlor; Kayleen Joyce; Claire M Magnuson; Jane Driano; Breanna Elger; Anne Lentino; Margaret Driscoll; Elise Tidwell; Apoorva Sharma; Sarah R Walker; Gretchen Jones; Poonam Sharma; Holly Stessman; Yanyuan Wu; Jay Vadgama; Dana Chase; Lesley Conrad; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  J Cancer Res Ther Oncol       Date:  2020-12-29

5.  Ovarian cancer in younger vs older women: a population-based analysis.

Authors:  J K Chan; R Urban; M K Cheung; K Osann; J Y Shin; A Husain; N N Teng; D S Kapp; J S Berek; G S Leiserowitz
Journal:  Br J Cancer       Date:  2006-10-31       Impact factor: 7.640

6.  Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.

Authors:  Vinicius Craveiro; Yang Yang-Hartwich; Jennie C Holmberg; Won Duk Joo; Natalia J Sumi; John Pizzonia; Brian Griffin; Sabrina K Gill; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Ayesha B Alvero; Gil Mor
Journal:  Cancer Med       Date:  2013-08-27       Impact factor: 4.452

7.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.

Authors:  C A Hamilton; M K Cheung; K Osann; L Chen; N N Teng; T A Longacre; M A Powell; M R Hendrickson; D S Kapp; J K Chan
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.